Post by
MedStocks2 on Jan 11, 2021 1:49pm
No follow through
Another big run in the stock and a complete lack of follow through to build in this momentum. Reincorporating in the USA and listing on the US market would virtually guarantee a huge shift in trading. Instead we are left having to maintain +.60 CAD while Sigilon skyrockets. Are we watching another bad rerun?
Comment by
MedStocks2 on Jan 11, 2021 4:55pm
lol. Wrong chart. In any case, it seems that SGTX value is 10x Sernova without much basis for it. Just tired of waiting for news I guess. If they are cashed up now with warrants, they need to get some preclinical data out on the immune system tech.
Comment by
BioTeck on Jan 12, 2021 11:35am
What makes you so sure they have pre-clinical data to release? They have been pretty low in funds for the last little while. Maybe with the exercise of warrants they can start to pull something together now but I doubt they have much else on the go other than the chicago clinical trial.
Comment by
Redbaron2211 on Jan 12, 2021 1:52pm
Would be nice to see a hault friday and resume trading on monday. IMO
Comment by
rixpix on Jan 12, 2021 2:07pm
Why would you want the stock halted if there is no real information to announce? And if there is something, announce it before the opening or after the close.
Comment by
Redbaron2211 on Jan 12, 2021 2:20pm
I'm speaking to the possibility of material information. Halt friday let them do the presentation, let a few rumors fly, release a robust update Monday morning before open. But who am I to say doesn't really matter in the long run.
Comment by
Sonny7 on Jan 12, 2021 3:16pm
Fair enough. I called it an opinion. I’m just more attracted to the foundation as opposed to spires and minarets
Comment by
BioTeck on Jan 13, 2021 12:43am
Sonny ol' chap, couldn't agree with you more.
Comment by
stockhunter1 on Jan 12, 2021 6:10pm
I think you will find many answers to your questions if you watch this H.C. Wainwright Bioconnect presentation and listen well, some should listen twice!! Phillip does a great job telling our story...to be sure. This Friday and the following week should be interesting. Good Luck to ALL Longs. https://journey.ct.events/view/3a577711-041b-48a3-8b1c-0d47129bb30c
Comment by
BioTeck on Jan 13, 2021 12:53am
What's it worth or what's it gonna cost?? Depends which pharma you ask. Stay rose rosy boy.
Comment by
BioTeck on Jan 13, 2021 12:51am
Don't patronize me rose boy. Obviously I am fully aware of hemacure but that was 2 years ago. Are you aware of that? Are you also aware nothing has happened since? Are you also aware a company worth 1 billion is cashing in on what we could have done 2 years ago?
Comment by
Redbaron2211 on Jan 13, 2021 8:51am
Bio they presented results on the hemophilia trials last May that's 8 moths ago. Next step is the clinic. Sure things might be slower with covid but no need to spread misinformation trying to give the impression this is a one trick pony. We all know your motives. I will stay positive, it has served me well. Cheers.
Comment by
BioTeck on Jan 13, 2021 9:26am
And how long after the trial was the presentation?? You know nothing John Rose.
Comment by
Redbaron2211 on Jan 13, 2021 9:44am
Bio good science takes time. I remember you were talking about how with the big money behind Semma they would be ahead of us in no time yet they haven't even started clinical trials. And why is a big company like SGTX only going after hemophilia?
Comment by
Redbaron2211 on Jan 13, 2021 2:23pm
Thanks stockhunter agree these are exciting times its nice to focus on the facts and embrace what could be a very positive out come for millions of people.
Comment by
BioTeck on Jan 13, 2021 11:26pm
When does the paper from the last placement hit the street?
Comment by
Redbaron2211 on Jan 14, 2021 12:05am
Jan 23rd, most that took place in the PP have a boat load of commons so I wouldn't expect that date being very significant. If they wanted to sell commons dont need to wait for those to come free trading.
Comment by
MedStocks2 on Jan 12, 2021 8:16pm
actually Red. That does make sense.